The NAMI Board of Directors charged the NAMI Policy Research Institute (NPRI) with examining the policy issues surrounding prescribing privileges for psychologists and to provide policy guidance to the Board. The report to the Board provides a comprehensive overview of the debate on prescribing privileges, describes a meeting of experts convened to explore issues pertaining to prescribing privileges and workforce shortages in the mental health field, and offers a set of recommendations to the Board on prescribing privileges and boundary-related issues affecting the availability of providers.
In 2002, Governor Gary Johnson of New Mexico signed into law a bill that grants licensed, doctoral-level psychologists who have completed a training and certification program the right to prescribe psychiatric medications. This is the first law of its kind (see New Mexico Law: Description and Analysis below.)
With passage of this law, attention is increasingly being riveted to policy questions surrounding whether psychologists should ever have the right to prescribe psychiatric medications and, if so, under what circumstances. The contentious debate about prescription privileges is occurring with concerns about limited access to care and severe workforce shortages in the mental health field as a backdrop.
The 1999 Surgeon General’s report revealed that less than one-third of all people with a diagnosable mental disorder in the U.S. receive treatment in a given year. And, the 1998 Schizophrenia PORT study revealed that fewer than 50% of all people with schizophrenia receive even minimally adequate treatment in a given year. These treatment access problems are even worse for children and adolescents with mental disorders.
One factor contributing to low rates of treatment and services for people with mental illnesses are the lack of qualified psychiatrists and other mental health providers in many parts of the country. There is compelling evidence that the nation's supply of psychiatrists is shrinking, and that access to treatment with psychiatrists is particularly limited for lower-income individuals who rely on public mental health systems for treatment and services.
These problems are particularly severe in rural parts of the country. In fact, in New Mexico, the lead proponent of the prescribing privileges legislation noted that only 18 psychiatrists of the state’s 90 licensed psychiatrists are located outside of Santa Fe or Albuquerque, whereas 175 of the 400 licensed psychologists in the state reside outside of these two population centers.
At the same time, since New Mexico’s law is the first of its kind, there is no clear evidence that affording prescription privileges to psychologists will increase access to timely treatment for individuals with mental illnesses who reside in rural communities. And, opponents of the legislation argue that psychologists are not adequately trained to prescribe medications and expanding prescription privileges to psychologists will therefore seriously compromise the quality of care, safety and well-being of vulnerable individuals with mental illnesses.
One solution proposed to address access to care barriers is to expand prescribing privileges to psychologists. Emboldened by success in passing legislation in New Mexico, it is anticipated that psychologists will push similar legislation in other states with renewed vigor in 2003 and beyond. In fact, task forces to explore the feasibility of expanding prescription privileges to psychologists have been formed in some states.
The issue of prescribing privileges has appeared at several levels; notably through state legislation, but also through initiatives by the federal government, as well as in the daily prescribing practices of general practitioners.
Since 1990, 12 states have rejected legislation to grant psychologists prescription privileges. These states (some of which have rejected prescribing legislation on multiple occasions) include Alaska, California, Connecticut, Florida, Georgia, Hawaii, Illinois, Louisiana, Missouri, Montana, Tennessee, and Texas. Not surprisingly, the state and federal chapters of the American Psychiatric Association and American Psychological Association have worked strenuously and expended considerable resources in opposition or support respectively of these legislative initiatives.
All 50 states and the District of Columbia authorize nurse practitioners or other advance practice nursing professionals to prescribe medications, including psychiatric medications, with certain conditions.
Nursing professionals authorized to prescribe medications include psychiatric nurse practitioners, clinical nurse specialists (psychiatric), certified nurse anesthetists and certified nurse midwives. Most laws authorizing advanced nursing professionals to prescribe medications contain limits in terms of practitioners authorized to prescribe, drug schedules under which they may prescribe, or supervisory/collaboration requirements.
For example, certain states (e.g. Arizona, California, Georgia, Guam, Maryland, Mississippi, New Hampshire, North Carolina, Oregon, South Dakota, Washington) limit prescribing authority to nurse practitioners, while others authorize a broader range of nursing professionals. And, some states impose restrictions on the types of drugs that these nursing professionals may prescribe. For example, Alabama, California, Florida, Hawaii, Kentucky, Mississippi, Nevada, and the Virgin Islands restrict prescribing privileges by authorized nursing professionals to "noncontrolled substances only", including antibiotics, analgesics, and anti-inflammatory medications, among others.
According to the American Psychological Association, 70% of psychiatric medications are today prescribed by general practitioners. General practitioners have extensive medical and pharmacology training, but may have limited training in psychiatry and psychopharmacology.
In 1989, Congress directed the Department of Defense (DoD) to create a Psychopharmacology Demonstration Project (PDP) to train military clinical psychologists to issue appropriate psychotropic medications to beneficiaries of the Military Health Services System. This program was operationalized in 1991.
Between 1991 and 1997, ten military psychologists completed the training program and were granted the right to prescribe medications.
Since New Mexico is the first state to authorize psychologists to prescribe medications, little research has been done on the impact of prescribing privileges for psychologists, including patient outcomes and safety factors. The only published research to date is on the DoD Demonstration Project (PDP).
Four separate evaluations were conducted of the DoD demonstration project. These evaluations yielded the following information across several parameters.
As stated above, New Mexico earlier this year became the first state to enact legislation granting authority to psychologists to prescribe psychiatric medications. The legislation creates a two step process for licensing psychologists to prescribe psychiatric medications.
Additional requirements are set forth in the New Mexico law for psychologists to maintain their general prescription certificates, including:
The New Mexico law specifies that physicians supervising psychologists with conditional prescribing certifications are individually responsible for the acts and omissions of the psychologist while under their supervision. It will be interesting to see if concerns about liability deter physicians from willingness to function as supervisors.
Even though the DoD curriculum was scaled back after year one, it still required significantly more academic training and clinical training and supervision than the New Mexico law requires. For example, the DoD curriculum required 660 hours of academic training versus 450 for the New Mexico curriculum. Additionally, the DoD curriculum required approximately 1,900 hours of clinical training versus a minimum of 400 hours to be granted conditional certification in New Mexico.
In the wake of last year’s New Mexico legislation, it is very likely that prescription privileges bills will be introduced in a number of additional states in FY 2003. Historically, NAMI-national has remained neutral on this issue as a matter of policy, and NAMI state organizations have adopted positions on state legislative proposals with little guidance from the national office. However, the accelerating pace of the prescription privileges debate made it timely to convene a group of experts and representatives from stakeholder organizations to examine the issues surrounding this debate.
On December 11, 2002, the NAMI Policy Research Institute (NPRI) convened a meeting of experts and stakeholders to discuss the complex issues surrounding the debate on prescribing privileges for psychologists, as well as serious human resource shortages in the mental health workforce. A series of presentations were provided offering the perspectives of psychiatrists, psychologists, psychiatric nurses, and county behavioral health directors on these issues. Based on input received at this meeting and
independent research conducted by staff, the following staff recommendations are set forth regarding NAMI’s Position on Prescribing Privileges for Psychologists and NAMI’s Advocacy Goals and Strategies.
Members of the taskforce include:
Supporters of prescription privileges for psychologists contend that safety concerns can be addressed through specialized training of psychologists who wish to obtain certification to prescribe medications. They argue that the current level of basic science training in graduation education in psychology is adequate to enable psychologists, with some additional specialized training, to safely and effectively prescribe psychiatric medications.
Opponents of prescription privileges for psychologists argue that graduate education for psychologists de-emphasizes the medical model in favor of a social and behavioral approach that trains psychologists to conduct psychological assessments and provide psychotherapy, not to provide medical treatment. They point out that psychotropic medications used to treat mental illnesses are very powerful, can cause potentially disabling and life-threatening side effects, and require particular expertise among those who prescribe and monitor them.
Additionally, they also emphasize the importance of experience and expertise in monitoring complex medication interactions, pointing out that over 50% of individuals with mental illnesses prescribed psychotropic medications also have other serious medical conditions requiring medications.